Adaptimmune Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Adaptimmune Therapeutics has been growing earnings at an average annual rate of 2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 56.5% per year.

Wichtige Informationen

2.0%

Wachstumsrate der Gewinne

14.9%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie17.0%
Wachstumsrate der Einnahmen56.5%
Eigenkapitalrendite-75.3%
Netto-Marge-51.3%
Nächste Ertragsaktualisierung13 Nov 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Sep 12

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 03

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10
Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Aug 03

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Jun 29

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Jun 19

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Mar 06

Circling Back On Adaptimmune Therapeutics

Dec 15

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Dec 02
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming

Sep 29

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Aug 14
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches

Jul 29

Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts

Jun 16

Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow

Jun 05

Aufschlüsselung der Einnahmen und Ausgaben

Wie Adaptimmune Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

NasdaqGS:ADAP Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Jun 24141-72790
31 Mar 2418-163770
31 Dec 2360-114720
30 Sep 2371-9561-67
30 Jun 2371-91610
31 Mar 2371-114590
31 Dec 2227-165610
30 Sep 2218-17563105
30 Jun 2212-176610
31 Mar 229-171600
31 Dec 216-158570
30 Sep 216-156560
30 Jun 216-149540
31 Mar 214-140500
31 Dec 204-130460
30 Sep 203-123430
30 Jun 202-127410
31 Mar 202-138410
31 Dec 191-137430
30 Sep 192-144430
30 Jun 1942-99430
31 Mar 1951-102440
31 Dec 1860-96440
30 Sep 1862-87420
30 Jun 1849-93390
31 Mar 1843-6936-19
31 Dec 1738-70310
30 Sep 1742-582917
30 Jun 1717-762632
31 Mar 1714-782468
31 Dec 1614-72230
30 Sep 1610-732363
30 Jun 1612-612157
31 Mar 1615-552148
31 Dec 1514-481840
30 Sep 1513-191429
30 Jun 1510-371024
31 Mar 157-16819
31 Dec 144-12516
30 Sep 142-13414
30 Jun 141-12310

Qualität der Erträge: ADAP is currently unprofitable.

Wachsende Gewinnspanne: ADAP is currently unprofitable.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: ADAP is unprofitable, but has reduced losses over the past 5 years at a rate of 2% per year.

Beschleunigtes Wachstum: Unable to compare ADAP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Erträge im Vergleich zur Industrie: ADAP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Eigenkapitalrendite

Hohe Eigenkapitalrendite: ADAP has a negative Return on Equity (-75.31%), as it is currently unprofitable.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren